Intratumoral injection of caerin 1.1 and 1.9 peptides increases the efficacy of vaccinated TC-1 tumor-bearing mice with PD-1 blockade by modulating macrophage heterogeneity and the activation of CD8+ T cells in the tumor microenvironment,Clinical & Translational Immunology

当前位置： X-MOL 学术 › Clin. Transl. Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Intratumoral injection of caerin 1.1 and 1.9 peptides increases the efficacy of vaccinated TC-1 tumor-bearing mice with PD-1 blockade by modulating macrophage heterogeneity and the activation of CD8+ T cells in the tumor microenvironment
Clinical & Translational Immunology ( IF 4.6 ) Pub Date : 2021-08-17 , DOI: 10.1002/cti2.1335
Guoying Ni _{1,

2,

3} , Xiaodan Yang ₃ , Junjie Li ₃ , Xiaolian Wu ₁ , Ying Liu ₁ , Hejie Li ₂ , Shu Chen ₁ , Conor E Fogarty ₂ , Ian H Frazer ₄ , Guoqiang Chen ₁ , Xiaosong Liu _{1,

2,

3} , Tianfang Wang ₂

Affiliation

Developing a vaccine formula that alters the tumor-infiltrating lymphocytes to be more immune active against a tumor is key to the improvement of clinical responses to immunotherapy. Here, we demonstrate that, in conjunction with E7 antigen-specific immunotherapy, and IL-10 and PD-1 blockade, intratumoral administration of caerin 1.1/1.9 peptides improves TC-1 tumor microenvironment (TME) to be more immune active than injection of a control peptide.

中文翻译：

瘤内注射 caerin 1.1 和 1.9 肽通过调节肿瘤微环境中的巨噬细胞异质性和 CD8+ T 细胞的激活，提高了接种了 PD-1 阻断剂的 TC-1 荷瘤小鼠的功效

开发一种疫苗配方，改变肿瘤浸润淋巴细胞，使其对肿瘤更具免疫活性，是改善免疫治疗临床反应的关键。在此，我们证明，与 E7 抗原特异性免疫疗法以及 IL-10 和 PD-1 阻断相结合，瘤内施用 caerin 1.1/1.9 肽可改善 TC-1 肿瘤微环境 (TME)，使其比注射 caerin 1.1/1.9 肽更具免疫活性。对照肽。

更新日期：2021-08-17

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文